# Ceregene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceregene

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.ceregene.com
- Total disclosed funding: $71M
- Latest round: Series D (Apr 3, 2012)
- Investors on record: 6

## About

Ceregene Inc. is a biotechnology company focused on developing innovative gene therapy products to address major neurodegenerative disorders, utilizing specialized gene delivery technologies for effective treatment solutions.Founded in 2001, Ceregene Inc. operates from San Diego, US, specializing in gene therapy development for neurodegenerative conditions. The company received funding through a TRADE SALE in August 2013 when Sangamo BioSciences Inc. acquired it for USD 1.000 mn. Ceregene has completed 10 deals since its inception, with its total capital raised amounting to USD 1.000 mn.Ceregene, Inc. specializes in the development of gene therapy products aimed at treating major neurodegenerative disorders, leveraging proprietary gene delivery technology to deliver neurotrophic growth factors. Their core product offerings include therapies designed for Alzheimer's disease and Parkinson's disease, which have successfully progressed through preclinical development and into clinical trials. These therapies seek to slow, halt, or potentially reverse neuronal degeneration, addressing critical gaps in treatment for conditions that currently lack effective solutions. Ceregene's client base primarily consists of healthcare professionals and institutions focused on neurology, as well as research organizations looking to explore innovative treatment options for neurodegenerative diseases. The company’s products are primarily marketed in North America and Europe, targeting healthcare providers and clinical research facilities engaged in the treatment of neurodegenerative disorders.Ceregene's revenue model is centered on partnerships with healthcare institutions and research organizations that seek advanced treatment options for neurodegenerative diseases. The company's transactions typically occur through collaborative agreements with clinical research centers, which may include joint research initiatives, clinical trials, and potential licensing agreements for the use of their proprietary gene therapy technologies. These collaborations allow Ceregene to monetize its innovative therapies while supporting the advancement of clinical research. While specific pricing details for individual products or services have not been disclosed, the revenue structure is likely structured around milestone payments, grants from research institutions, and potential royalties from successful commercialization of their gene therapies. The company's flagship offerings are set against the backdrop of a growing demand for effective neurodegenerative disease treatments, reinforcing the need for innovative solutions in the healthcare market.Ceregene plans to develop new products targeting neurodegenerative diseases, although specific release dates are not provided. There are intentions to expand into international markets, particularly in regions that show a growing demand for such therapies. The recent acquisition facilitated by Sangamo BioSciences Inc. is expected to support these initiatives, particularly through the utilization of the USD 1.000 mn raised during the TRADE SALE.

## Funding rounds

- Series D, Apr 3, 2012, $7.7M — Alta Partners, MPM BioImpact
- Series D, Nov 11, 2010, $3.8M — Alta Partners, Hamilton BioVentures, Patricia Industries, MPM BioImpact
- Series C, Jan 25, 2007, $27M — Alta Partners, Hamilton BioVentures, California Technology Ventures, Patricia Industries, MPM BioImpact, Cell Genesys Inc.
- Series B, Aug 4, 2004, $32M — Alta Partners, Hamilton BioVentures, California Technology Ventures, MPM BioImpact

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C, Series D
- Hamilton BioVentures (https://capitalatlas.ai/funds/hamilton-bioventures) — Series B, Series C, Series D
- California Technology Ventures (https://capitalatlas.ai/funds/california-technology-ventures) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C, Series D
- Patricia Industries (https://capitalatlas.ai/funds/patricia-industries) — Series C, Series D
- Cell Genesys Inc. — Series C